Osteoporosis in men: what changed?


Authors: Tomková Soňa;  Vrško Martin
Authors‘ workplace: Interná klinika LF UPJŠ a Nemocnice Košice-Šaca, Košice
Published in: Clinical Osteology 2019; 24(3): 93-100
Category:

Overview

Osteoporosis, in which the bones become porous and break easily, is one of the world´s most common and debilitating diseases. The lifetime risk for osteoporotic fracture in older men may range from 13 to 25 %. Although it affects men less commonly than woman, men who do sustain fractures may suffer more severely in terms of the quality and quantity of their lives than when fractures occur in woman. Unfortunately, lack of doctors are not aware of the problem of osteoporosis in men, and the identification of people at risk is far from being a standard practice. Osteoporosis can, to a certain extent, bez prevented, it can be easily diagnosed and effective treatments are available, let´s make a choice.

Keywords:

diagnosis – epidemiology – classification – osteoporosis in men – treatment


Sources
  1. Bliuc D, Nguyen ND, Milch VE et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and woman. JAMA 2009; 301(5): 513–521. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2009.50>.
  2. Adler RA. Update on osteoporosis in men. Best Pract Res Clin Endocrinol Metab 2018; 32(5): 759–772. Dostupné z DOI: <http://dx.doi.org/10.1016/j.beem.2018.05.007>.
  3. Solomon DH, Johnston SS, Boytsov NN et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 2014; 29(9): 1929–1937. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.2202>.
  4. Jennings LA, Auerbach AD, Maselli J et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture, J Am Geriatr Soc 2010; 58(4): 650–657. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1532–5415.2010.02769.x>.
  5. Hopkins RB, Pullenayegum E, Goeree R et al. Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int 2012; 23(3): 921–927. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–011–1652–8>.
  6. Pasco JA, Lane SE, Brennan SL et al. Fracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data. Osteoporos Int 2014; 25(3): 857–862. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–013–2561–9>.
  7. Wright NC, Saag KG, Dawson-Hughes B et al. The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. Osteoporos Int 2017; 28(11): 1225–1232. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–017–4207–9>.
  8. Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med 1986; 314(26): 1676–1686. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM198606263142605>.
  9. Harman SM, Metter EJ, Tobin JD et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001; 86(2): 724–731. Dostupné z DOI: <http://dx.doi.org/10.1210/jcem.86.2.7219>.
  10. Adler RA. Osteoporosis in men: insights for the clinician. Ther Adv Musculoskel Dis 2011; 3(4): 191–200. Dostupné z DOI: <http://dx.doi.org/10.1177/1759720X11411600>.
  11. Rosen CJ, Kurland ES, Vereault D et al. Association between serum IGF-I and a simple sequence repeat inf the IFG-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998; 83(7): 2286–2290. Dostupné z DOI: <http://dx.doi.org/10.1210/jcem.83.7.4964>.
  12. Ebeling PR. Clinical practice. Osteoporosis in men. J Eng J Med 2008; 358(14): 1474–1482. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMcp0707217>.
  13. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23(34): 8580–8587. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2005.02.8670>.
  14. Antonio L, Wu FCV, O´Neil TW et al. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab 2016; 101(7): 2647–2657. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2015–4106>.
  15. Khosla S, Melton LJ, Atkinson EJ et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86(8): 3555–3561. Dostupné z DOI: <http://dx.doi.org/10.1210/jcem.86.8.7736>.
  16. Javaid MK, Cooper C. Prenatal and childhood influences on osteoporosis. Best Pract res Clin Endocrinol Metab 2002; 16(2): 349–367. Dostupné z DOI: <http://dx.doi.org/10.1053/beem.2002.0199>.
  17. Snyder PJ, Kopperdahl DL, Stephens-Shields AJ et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone. A controlled clinical trial. JAMA Intern Med 2017; 177(4): 471–479. Dostupné z DOI: <http://dx.doi.org/10.1001/jamainternmed.2016.9539>.
  18. Watts NB, Adler RA, Bilezikian JP et al. Osteoporosis in men: an endocrine society clinical practice guidelines. J Clin Endocrinol Metab 2012; 97(6):1802–1822. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011–3045>.
  19. Alswat KA. Gender Disparities in Osteoporosis. J Clin Med Res 2017; 9(5): 382–387. Dostupné z DOI: <http://dx.doi.org/10.14740/jocmr2970w>.
  20. Mackey DC, Lui LY, Cawthon PM et al. High-trauma fractures and low bone mineral density in older women and men. JAMA 2007; 298(20): 2381–2388. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.298.20.2381>.
  21. van Staa TP, Leufkens HGM, Abenheim I et al. Oral corticosteroids and fracture risk: relationship to daily nad cumulative doses. Rheumatology (Oxford) 2000; 39(12): 1383–1389. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/39.12.1383>.
  22. Waljee AK, Rogers MA, Lin P et al. Short term use of oral corticosteroids nad related harms among adults in the United States: population based cohort study. BMJ 2017; 357: j1415. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.j1415>.
  23. Kaze AD, Rosen HN, Paik JM. A meta-analysis of teh association between body mass index and risk of vertebral fracture. 2018; 29(1): 31–39. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–017–4294–7>.
  24. Jean S, O´Donnell S, Lagace C et al. Trends in hip fracture rates In Canada: an age-period-cohort analysis. J Bone Miner Res 2013; 28(6): 1283–1289. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1863>.
  25. Khosla S, Shane E. A crisis in the treatment of osteoporosis. J Bone Miner Res 2016; 31(8): 1485–1487. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.2888>.
  26. Odborné usmernenie MZ SR pre diagnostiku a liečbu osteoporózy 2006. Dostupné z WWW: <http://www.osteoporoza.sk/fileadmin/osteoporoza/lekari/Guidelines_a_knihy/Vestnik_MZSR_-_osteoporoza.pdf>.
  27. Chaganti RK, Parimi N, Lang T et al. Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporotic Fractures in Men (MrOS) Study Group. Osteoporos Int 2010; 21(8): 1307–1316. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–009–1105–9>.
  28. Orwoll E, Teglbjærg CS, Langdahl BL et al. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. J Clin Endocrin Metab 2012; 97(9): 3161–3169. Dostupné z DOI: <https://doi.org/10.1210/jc.2012–1569>.
  29. Orwoll E, Teglbjærg CS, Langdahl BL et al. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. J Clin Endocrin Metab 2012; 97(9): 3161–3169. Dostupné z DOI: <https://doi.org/10.1210/jc.2012–1569>.
  30. Tomková S, Beličáková Z. Osteoporóza u mužov. Via Pract 2009; 6(9): 350–352.
  31. Orwoll E ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343(9): 604–610. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200008313430902>.
  32. Ringe JD, Faber H, Farahmand P et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006; 26(5): 427–431. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296–005–0004–4>.
  33. Zoznam kategorizovaných liekov 1. 7. 2019–31. 7. 2019. Časť B: indikačné obmedzenia. Ministerstvo zdravotnícka Slovenskej republiky. Dostupné z WWW: <https://www.health.gov.sk/Clanok?lieky201907>.
  34. Boonen S, Reginster JY, Kaufman JM et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367(18): 1714–1723. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1204061>.
  35. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22(10): 1479–1491. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.0707onj>.
  36. Shane E, Burr D, Abrahamsen B et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29(1): 1–23. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1998>.
  37. Unnanuntana A, Jarusriwanna A, Songcharoen P. Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax). PLoS One 2017; 12(7): e0180325. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0180325>.
  38. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296(24): 2927–2938. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.296.24.2927>.
  39. Black DM, Reid IR, Boonen S et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27: 243–254. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1494>.
  40. Langdahl B, Teglbjaerg CS, Ho PR et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab 2015; 100(4): 1335–1342. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014–4079>.
  41. Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361(8): 745–755. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0809003>.
  42. Kendler DL, Roux C, Benhamou CL et al. Effects of denosumab on bone mineral density and bone turnover in post-menopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25(1): 72–81. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.090716>.
  43. Anastasilakis AD, Polyzos SA, Makras P et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017; 32(6): 1291–1296. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.3110>.
  44. Orwoll ES, Shceele WH, Paul S et al. The effect of teriparatide (human parathyroid hormone 1–34) therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18(1): 9–17. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.2003.18.1.9>.
  45. Miller PD, Hattersley G, Riis BJ et al. Effects of abaloparatide on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 2016; 316(7): 722–733. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.11136>.
  46. Kaufman JM, Orwoll E, Goemaere S et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: 36 month results. Osteoporos Int 2005; 16(5): 510–516. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–004–1713–3>
  47. Crandal CJ, Newberry SJ, Diamant A et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 2014; 161(10): 711–723. Dostupné z DOI: <http://dx.doi.org/10.7326/M14–0317>.
  48. Center JR, Bliuc D, Nguyen TV et al. Risk of subsequent fracture after low-trauma fracture in men and woman. JAMA 2007; 297(4): 387–394. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.297.4.387>.
  49. Bliuc D, Center JR. Determinants of mortality risk following osteoporotic fractures. Curr Opin Rheumatol 2016; 28(4): 413–419. Dostupné z DOI: <http://dx.doi.org/10.1097/BOR.0000000000000300>.
  50. Payer J, Killinger Z. Osteroporóza. Herba: Bratislava 2012. ISBN 978–80–89171–84–1.
  51. Kanis JA, Borgstrom F, Compston J et al. SCOPE: a scorecard of osteoporosis in Europe. Arch Osteoporos 2013; 8: 144. Dostupné z DOI: <http://dx.doi.org/10.1007/s11657–013–0144–1>.
  52. Herrea A, Lobo-Escolar A, Mateo J et al. Male osteoporosis: A review. World J Orthop 2012; 3(12): 223–234. Dostupné z DOI: <http://dx.doi.org/10.5312/wjo.v3.i12.223>.
  53. Tomková S,Telepková D. Sekundárna osteoporóza. Via Pract 2005; 2(11): 446–449.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics Radiodiagnostics Rehabilitation Rheumatology Traumatology fenix.admin.empty
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account